Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Julen Viana-Errasti
Observed names:
Viana Errasti, Julen,
Viana-Errasti, Julen
Institution:
Institut d'Investigació Biomédica de Bellvitge
Observed institutions:
Institut d'Investigació Biomédica de Bellvitge,
Institut Català d'Oncologia,
Centro de Investigación Biomédica en Red de Cáncer,
Universitat de Barcelona
ORCID:
0000-0002-9672-6951
Observed ORCID:
0000-0002-9672-6951
OpenAlex ID:
A5029377574
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
2023
·
Pilar Mur
, Julen Viana-Errasti
, et al.
·
Genome Medicine
·
33
PDF
TET1 and TDG Suppress Inflammatory Response in Intestinal Tumorigenesis: Implications for Colorectal Tumors With the CpG Island Methylator Phenotype
2023
·
Rossella Tricarico
, Jozef Madzo
, et al.
·
Gastroenterology
·
33
PDF
Genetics, genomics and clinical features of adenomatous polyposis
2025
·
Jihoon E. Joo
, Julen Viana-Errasti
, et al.
·
Familial Cancer
·
25
PDF
MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes
2023
·
Mariona Terradas
, Noemi Gonzalez-Abuin
, et al.
·
European Journal of Human Genetics
·
18
PDF
Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
·
Cancer Research Communications
·
17
PDF
Comparative Analysis of Somatic and Germline Polymerase Proofreading Deficiencies in Cancer: Molecular and Clinical Implications
2025
·
Julen Viana-Errasti
, Raúl Marín
, et al.
·
Modern Pathology
·
9
PDF
From Rare to Common: Genetic Insights into TLR7 Variants in a Multicentric Spanish Study on COVID-19 Severity
2025
·
Arnau Antolí
, Gardenia Vargas-Parra
, et al.
·
Journal of Clinical Immunology
·
8
PDF
Autoantibodies neutralizing type I interferons remain a significant risk factor for critical COVID-19 pneumonia in vaccinated patients
2025
·
Arnau Antolí
, José Luis Gómez-Vázquez
, et al.
·
Clinical Immunology
·
7
Germline NPAT inactivating variants as cause of hereditary colorectal cancer
2024
·
Mariona Terradas
, Stephanie A. Schubert
, et al.
·
European Journal of Human Genetics
·
5
PDF
Constitutional epimutations in LTBP4, a component of the TGF-β signaling, and in BRCA1, as potential drivers of early-onset colorectal cancer
2025
·
Mariona Terradas
, Pilar Mur
, et al.
·
Clinical Epigenetics
·
2
PDF
Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors
2022
·
Shreya M. Shah
, Elena V. Demidova
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Supplementary datasets for "Improving interpretation of POLE and POLD1 genetic variants in cancer using clinical, in silico, and functional data"
2026
·
Viana Errasti, Julen
·
Zenodo (CERN European Organization for Nuclear Research)
Correction: Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
·
Cancer Research Communications
FIGURE 3 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
FIGURE 2 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 6 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
FIGURE 1 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 5 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 4 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 2 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Data from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 3 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
FIGURE 3 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 7 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Supplementary Table 1 from Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity
2024
·
Shreya M. Shah
, Elena V. Demidova
, et al.
Show more works
View as search
Works count:
39
Citation count:
158
H-index:
7
I10-index:
5
Year
Topic
Type